Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice CT

This study has been completed.
Information provided by (Responsible Party):
Ono Pharmaceutical Co. Ltd
ClinicalTrials.gov Identifier:
First received: April 3, 2006
Last updated: June 12, 2012
Last verified: June 2012
The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for multi-slice CT.

Condition Intervention Phase
Coronary Artery Disease
Drug: ONO-1101
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice Computed Tomography (CT) Due to Suspected Coronary Artery Disease

Resource links provided by NLM:

Further study details as provided by Ono Pharmaceutical Co. Ltd:

Primary Outcome Measures:
  • heart rate
  • image quality
  • safety

Estimated Enrollment: 90
Study Start Date: April 2006

Ages Eligible for Study:   20 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 20-74 years old
  2. Heart rate less than 90 beats/min more than 70 beats/min at entering the CT room

Exclusion Criteria:

  1. Previous allergic reactions to contrast agent
  2. Renal failure
  3. Asthma
  4. Other exclusion criteria as specified in the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00311038

Hokuriku Region Facility
Hokuriku, Japan
Kanto Region Facility
Kanto, Japan
Kyusyu Region Facility
Kyusyu, Japan
Sponsors and Collaborators
Ono Pharmaceutical Co. Ltd
Study Director: Project Leaders Development Planning Ono Pharmaceutical Co. Ltd
  More Information

Responsible Party: Ono Pharmaceutical Co. Ltd
ClinicalTrials.gov Identifier: NCT00311038     History of Changes
Other Study ID Numbers: ONO-1101-24 
Study First Received: April 3, 2006
Last Updated: June 12, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Ono Pharmaceutical Co. Ltd:
Landiolol Hydrochloride
Multi-slice CT
Coronary Artery Disease

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Heart Diseases
Vascular Diseases
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016